MYDA-MUSIC: Myocardial Damage and Music Study

Sponsor
San Filippo Neri General Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03507361
Collaborator
(none)
443
1
2
43
10.3

Study Details

Study Description

Brief Summary

MYDA-MUSIC study is a randomized, double blind (operator and analyst) study performed in San Filippo Neri Hospital, Roma, Italy and in Di Venere Hospital, Bari, Italy. The planned study duration is 12 months. The objectives are to assess the effects of heart-rate-variability based music on the incidence and magnitude of peri-procedural myocardial damage caused by coronary angioplasty in stable patients. 443 patients with chronic stable angina scheduled for a coronary angiography and possible ad hoc angioplasty will be randomized to receive music or dumb earphones.

Condition or Disease Intervention/Treatment Phase
  • Other: HRV-BASED MUSIC
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
443 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Heart Rate Variability-based Music for the Prevention of PCI-related Myocardial Injury
Actual Study Start Date :
May 2, 2018
Anticipated Primary Completion Date :
May 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: MUSIC

Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure

Other: HRV-BASED MUSIC
Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.

No Intervention: DUMB EARPHONES

Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.

Outcome Measures

Primary Outcome Measures

  1. Incidence of procedure-related myocardial injury [within 24 hours from interventional procedure]

    c-TnI concentration >99th percentile URL in at least 1/3 blood drawings

Secondary Outcome Measures

  1. Overall satisfaction with the procedure [From 5 to 30 minutes after the interventional procedure]

    Self-evaluation test on an analogic visual scale (score range 1-10, higher stress for higher values)

  2. Difference in Distress self-evaluation baseline and after the intervention [Baseline and from 5 to 30 minutes after the interventional procedure]

    Self-evaluation test on an analogic visual scale (score range 1-10, higher stress for higher values)

  3. Evaluation of pain experienced during the interventional procedure [Baseline and from 5 to 30 minutes after the interventional procedure]

    Self-evaluation test (score range 1-10, higher pain for higher values)

  4. Difference in Anxiety evaluation baseline and after the intervention [Baseline and from 5 to 30 minutes after the interventional procedure]

    State-Trait Anxiety Inventory (STAI) test - Y italian version (score range 20-80, the higher the score the more anxiety the patients has, 2 subscales)

  5. Questionnaire regarding a narrative report of the procedure [From 5 to 30 minutes after the interventional procedure]

    Categorical analysis evaluated with a dedicated software analysing unstructured written narration of the experience of their invasive procedure.

  6. Changes in Mean Heart rate during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (recorded for 5 to 10 minutes)]

    Calculation of Mean HR (beats/minute) on ECG samples recorded for 5 to 10 minutes

  7. Changes in RR during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of Mean RR interval (msec) on 5 to 10 minutes duration ECG samples.

  8. Changes in SDNN during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of SDNN (msec) on 5 to 10 minutes duration ECG samples.

  9. Changes in RMSSD during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of RMSSD (msec) on 5 to 10 minutes duration ECG samples.

  10. Changes in pNN50 during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of pNN50 (%) on 5 to 10 minutes duration ECG samples.

  11. Changes in pNN20 during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of pNN20 (%) on 5 to 10 minutes duration ECG samples.

  12. Changes in pNN10 during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of pNN10 (%) on 5 to 10 minutes duration ECG samples.

  13. Changes in pNN05 during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of pNN05 (%) on 5 to 10 minutes duration ECG samples.

  14. Changes in SD1 during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of SD1 (msec) on 5 to 10 minutes duration ECG samples.

  15. Changes in SD2 during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of SD2 (msec) on 5 to 10 minutes duration ECG samples.

  16. Changes in SD1/SD2 during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of SD1/SD2 ratio (number) on 5 to 10 minutes duration ECG samples.

  17. Changes in VB during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of VB (sec) on 5 to 10 minutes duration ECG samples.

  18. Changes in Stress index during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of stress index (number) on 5 to 10 minutes duration ECG samples.

  19. Changes in CV during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of CV (number) on 5 to 10 minutes duration ECG samples.

  20. Changes in Power of frequency domains during the procedure (Heart rate variability measure) [Baseline and at 5 minutes intervals (5 to 10 minutes duration)]

    Calculation of the power of VLF, LF, HF and total frequency-domain power on 5 to 10 minutes duration ECG samples (ms2)

  21. Postprocedural c-TnI peak concentration in patients undergoing coronary angioplasty [within 24 hours from interventional procedure]

    Highest concentration in c-TnI in 3 blood samples

  22. Time-to-peak in c-TnI concentration in patients undergoing coronary angioplasty [within 24 hours from interventional procedure]

    Time-to-Highest concentration in c-TnI in 3 blood samples

  23. Incidence of procedure-related myocardial infarction (myocardial infarction type 4a) in patients undergoing coronary angioplasty [within 24 hours from interventional procedure]

    c-TnI concentration >10 x the 99th percentile in at least 1/3 blood drawings

  24. Incidence of in-hospital Major Adverse Cardiac Events in patients undergoing coronary angioplasty [Through study completion (average of 3 days)]

    Incidence of death, myocardial infarction, unplanned revascularization

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Chronic stable angina scheduled to undergo a coronary angiography and ad-hoc angioplasty
Exclusion Criteria:
  • Abnormal c-TnI level before angiography

  • Participation in other clinical studies

  • Patients with pacemakers or defibrillators

  • High rate atrial fibrillation (baseline heart rate >99 bpm) at enrolment

Contacts and Locations

Locations

Site City State Country Postal Code
1 San Filippo Neri General Hospital Roma RM Italy 00152

Sponsors and Collaborators

  • San Filippo Neri General Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christian Pristipino, Principal investigator, San Filippo Neri General Hospital
ClinicalTrials.gov Identifier:
NCT03507361
Other Study ID Numbers:
  • V1-Jan31-2018
First Posted:
Apr 25, 2018
Last Update Posted:
Apr 4, 2019
Last Verified:
Apr 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 4, 2019